The broad federal budget bill approved by US House and Senate negotiators on 16 December offers relief to sponsors of pending marketing applications for insulin, human growth hormone and other protein agents that are scheduled to transition to biologic status beginning early next year.
The legislation, which must be approved by Congress and the White House by 20 December, would require the Food and...







